Genmab/GMAB

$29.20

-0.68%
-
1D1W1MYTD1YMAX

About Genmab

Genmab A/S is a Denmark-based international biotechnology company. It specializes in the creation and development of antibody therapeutics for the treatment of cancer. The Company is the creator of the approved antibodies: DARZALEX (daratumumab) for the treatment of certain multiple myeloma indications, Kesimpta for the treatment of adults with relapsing forms of multiple sclerosis, TEPEZZA (teprotumumab) for the treatment of thyroid eye disease and FASPRO, for the treatment of adult patients with certain multiple myeloma indications. The first approved Genmab created therapy Arzerra, approved for the treatment of certain chronic lymphocytic leukemia indications, is available in Japan and is also available in other territories via compassionate use or oncology access programs. Genmab develops a broad clinical and pre-clinical product pipeline, and owns four antibody technologies, DuoBody bispecific platform, HexaBody platform, DuoHexaBody platform & HexElect platform.

Ticker

GMAB

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Jan Van De Winkel

Employees

2,204

Headquarters

Koebenhavn v, Denmark

Genmab Metrics

BasicAdvanced
$19.31B
Market cap
30.41
P/E ratio
$0.96
EPS
0.92
Beta
-
Dividend rate

What the Analysts think about Genmab

Analyst Ratings

Majority rating from 11 analysts.
Buy

Price Targets

Average projection from 11 analysts.
38.08% upside
High $51.00
Low $28.00
$29.20
Current price
$40.32
Average price target

Genmab Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
13.68% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
Kr4.68B
-1.39%
Net income
Kr640M
-69.94%
Profit margin
13.68%
-69.51%

Genmab Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 96.49%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
$0.05
$0.30
$0.47
$0.14
-
Expected
$0.65
$2.18
$3.14
$3.99
$2.25
Surprise
-92.4%
-86.2%
-84.96%
-96.49%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.
ADR

Upcoming events

Buy or sell Genmab stock

Buy or sell Genmab stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing